Routine post-dilatation at nominal volume to optimise the expansion of balloon-expandable valves: the DOUBLE-TAP study
EuroIntervention · 2025-10 · 21 (19) · e1159-e1168
DOI: 10.4244/eij-d-25-00258 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift EuroIntervention, 2025-10. Verfasst von Ali Husain und 17 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Balloon Valvuloplasty, Aortic Valve Stenosis, Heart Valve Prosthesis. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Incomplete expansion of balloon-expandable (BE) transcatheter heart valves (THVs) is sometimes treated by ad hoc post-dilatation with an overfilled or larger valvuloplasty balloon. The efficacy of this approach has not been rigorously evaluated, although increased risk for adverse events has been demonstrated. Observational experience suggests that post-dilatation using the original delivery system balloon at the identical filling volume (i.e., double-tap) may routinely improve the degree of THV expansion with low risk. AIMS: We sought to assess the safety and efficacy of a strategy of routine double-tap after BE transcatheter aortic valve implantation (TAVI). METHODS: Patients undergoing TAVI with the SAPIEN 3 Ultra (S3U) valve were prospectively included. Patients with severe annular or subannular calcification were excluded. A validated method of fluoroscopic analysis was utilised to assess the cross-sectional area at the inflow, midpoint, and outflow of the THV before and after double-tap. Thirty-day clinical outcomes were documented. RESULTS: Routine double-tap was performed in 102 patients. Despite nominal deployment, all patients had some degree of THV underexpansion after the first inflation. Fluoroscopic analysis documented an increase in minimal THV expansion by cross-sectional area of 9.8% for the 20 mm S3U (p=0.151), 9.9% for the 23 mm S3U (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
- Sheikh Jaber Al-Ahmad Hospital, Kuwait City, Kuwait.
- Department of Cardiology, University and Hospital of Fribourg, Fribourg, Switzerland.
- Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
- Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Zitieren
APA
Husain, A., Jelisejevas, J., Millar, K., Alnuwakhtha, A., Ferkh, A., Delarive, J., Gill, H., Althekrallah, J., Offen, S., Tzimas, G., Ye, J., Leipsic, J. A., Blanke, P., Sathananthan, J., Wood, D. A., Sellers, S. L., Meier, D., & Webb, J. G. (2025). Routine post-dilatation at nominal volume to optimise the expansion of balloon-expandable valves: the DOUBLE-TAP study. EuroIntervention, 21(19), e1159-e1168. https://doi.org/10.4244/eij-d-25-00258
Vancouver
Husain A, Jelisejevas J, Millar K, Alnuwakhtha A, Ferkh A, Delarive J, et al. Routine post-dilatation at nominal volume to optimise the expansion of balloon-expandable valves: the DOUBLE-TAP study. EuroIntervention. 2025;21(19):e1159-e1168. doi:10.4244/eij-d-25-00258
BibTeX
@article{Husain2025,
author = {Husain, Ali and Jelisejevas, Julius and Millar, Kevin and Alnuwakhtha, Abdulla and Ferkh, Aaisha and Delarive, Julien and Gill, Hacina and Althekrallah, Jasem and Offen, Sophie and Tzimas, Georgios and Ye, Jian and Leipsic, Jonathon A and Blanke, Philipp and Sathananthan, Janarthanan and Wood, David A and Sellers, Stephanie L and Meier, David and Webb, John G},
title = {Routine post-dilatation at nominal volume to optimise the expansion of balloon-expandable valves: the DOUBLE-TAP study},
journal = {EuroIntervention},
year = {2025},
volume = {21},
number = {19},
pages = {e1159--e1168},
doi = {10.4244/eij-d-25-00258}
}
EUVIMED